open access to scientific and medical research
Open access peer-reviewed scientific and medical journals.
Dove Medical Press is a member of the OAI.
Bulk reprints for the pharmaceutical industry.
We offer real benefits to our authors, including fast-track processing of papers.
Register your specific details and specific drugs of interest and we will match the information you provide to articles from our extensive database and email PDF copies to you promptly.
Back to Journals » Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy » Volume 15
Authors Jin H, Chen P, Zhang S, Wu P, Yu X
Received 1 July 2022
Accepted for publication 16 September 2022
Published 11 October 2022 Volume 2022:15 Pages 3103—3110
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Gian Paolo Fadini
Hua Jin, Peihong Chen, Shan Zhang, Ping Wu, Xuemei Yu
Department of Endocrinology and Metabolism, Fengxian Central Hospital, Shanghai, 201404, People’s Republic of China
Correspondence: Xuemei Yu, Department of Endocrinology and Metabolism, Fengxian Central Hospital, No. 6600, Nanfeng Road, Nanqiaoxincheng, Fengxian District, Shanghai, 201404, People’s Republic of China, Tel +86 21-57413468, Email [email protected]
Objective: To determine the levels of serum iron, ferritin, total iron-binding capacity, and hepcidin in patients with type 2 diabetes mellitus (T2DM), and to elucidate the relationship of these biomarkers with lower extremity arterial disease (LEAD).
Methods: Three hundred fifteen patients with T2DM were selected for the study and divided into non-LEAD (n = 119) and LEAD groups (n=196) based on the ankle-brachial index (ABI) results. Demographic data and clinical test results were collected from all patients. Serum iron, ferritin, total iron-binding capacity, and hepcidin levels were measured, and the transferrin saturation was calculated.
Results: Hepcidin levels were substantially higher in the LEAD group (19.17 ± 8.66 ng/mL) than the non-LEAD group (15.44± 7.55 ng/mL, P < 0.001), and there was a negative correlation between the ABI and serum lecithin level (r = − 0.349, P < 0.001). There were no other correlations with the other iron metabolism indicators. The results of dichotomous logistic regression with LEAD as the dependent variable revealed that smoking history (OR = 4.442, P = 0.008), hypertension history (OR = 3.721, P = 0.006), cardiovascular disease history (OR = 11.126, P < 0.001), diabetes duration (OR = 1.305, P < 0.001), age (OR = 1.056, P = 0.021), hs-CRP level (OR = 1.376, P = 0.002), HbA1c concentration (OR = 1.394, P = 0.001), and hepcidin level (OR = 1.097, P = 0.003) were independent risk factors for LEAD in T2DM patients.
Conclusion: Serum hepcidin levels were elevated in the LEAD group compared with the non-LEAD group, and elevated hepcidin levels were associated with the development of LEAD in T2DM patients, suggesting that hepcidin may be involved in the occurrence and development of LEAD in T2DM patients.
Keywords: hepcidin, type 2 diabetes mellitus, lower extremity arterial disease, ankle-brachial index
Type 2 diabetes mellitus (T2DM) is a chronic metabolic condition with numerous consequences that can affect multiple organs. According to the most recent epidemiologic census, the prevalence of diabetes among adults in China was as high as 11.2% in the national sample from 2015–2017.1 In 2019, the global diabetes prevalence is expected to reach 9.3% (463 million people).2
Lower extremity arterial disease (LEAD), a potentially fatal consequence of diabetes, is characterized by atherosclerotic stenosis or occlusion of the lower extremities (lower extremity atherosclerosis). Diabetic patients have a higher incidence and prevalence of LEAD than non-diabetic adults.3 LEAD, with atherosclerosis as the most prevalent pathologic alteration, is one of the most common consequences of T2DM. Indeed, T2DM patients have a 2-fold higher risk of LEAD than the general population.4 Of approximately 5000 newly-diagnosed T2DM patients in the UK Prospective Diabetes Study, 1.2% had LEAD at the time of diagnosis.5
The ankle-brachial index (ABI), a ratio of the systolic pressure of the ankle artery to the brachial artery, is commonly used to test for LEAD. Iron is a powerful oxidant that has been linked in vivo to the development of atherosclerosis. Diabetes mellitus is linked to iron overload (IO). IO may cause vasodilatory dysfunction and atherosclerosis by altering lipid profiles, sustaining endothelial activation, elevating inflammatory mediators, altering vascular permeability, and decreasing nitric oxide availability, thus resulting in vasodilatory dysfunction and atherosclerosis. A number of studies have verified the positive link between serum ferritin (SF) expression and the incidence of diabetes, yet there are unresolved issues: 1. The link between SF and LEAD. Is a high SF level the cause of LEAD or a consequence of the pathogenesis? The specific link and interaction concept requires additional investigation. 2. It is necessary to determine whether SF is an independent risk factor for LEAD. 3. The sites of iron and low-density lipoprotein-cholesterol (LDL-C) interaction and the implications for treatment are unknown.6
Hepcidin controls the quantity of iron in the blood by regulating the amount of ferroportin on the surface of enterocytes, hepatocytes, macrophages, and enterocytes.7 Recent evidence suggests that hepcidin, by delaying or blocking iron mobilization from macrophages, may cause atherosclerosis and is linked to an increased risk of cardiovascular disease.8 The onset and progression of T2DM is influenced by iron metabolism, either directly or indirectly. The soluble transferrin receptor-to-ferritin ratio is inversely associated with the incidence of T2DM, and high serum ferritin is one of the risk factors for T2DM.9
Recent evidence suggests that insulin therapy, as well as other diabetic medications, impacts hepcidin synthesis, hence changing the iron burden in cells. Iron load correction via hepcidin expression might be a unique and crucial mechanism of action for diabetic medications.10
Few clinical studies have been reported on the relationship between in vivo iron metabolism levels and LEAD in the T2DM population. Numerous cellular and metabolic functions, such as oxygen transport and energy metabolism, depend on iron. Hepcidin, a master regulator of iron homeostasis, maintains intracellular and circulating iron levels. The only known “iron exporter” that moves ferrous iron from within cells to the plasma is the transmembrane protein, ferroportin.11 Inflammatory cytokines, particularly IL-6 and IL-1, increase the expression of hepcidin.12 With an emphasis on hepcidin, the main regulator of body iron homeostasis, more recent in vitro and animal investigations have clarified the complicated signaling pathways controlling iron.13
This study aimed to evaluate the association between serum iron (Fe) metabolic indices and LEAD in individuals with T2DM and to offer novel insights into the processes underlying LEAD formation.
Three hundred fifteen patients with T2DM hospitalized in the Endocrinology Department of Fengxian District Central Hospital in Shanghai from January 2016 to October 2019 were selected. According to the ankle-brachial index (ABI) values, the patients were separated into two groups: non-LEAD (n = 119); and LEAD (n = 196). The T2DM inclusion criteria were as follows: meeting the diagnostic criteria of diabetes mellitus established by WHO in 2011 (fasting glucose ≥ 7.0 mmol/L, glycosylated hemoglobin [HbA1c] ≥ 6.5%, and/or 2 h postprandial glucose ≥ 11.1 mmol/L). The exclusion criteria were as follows: type 1 diabetes; special types of diabetes; acute complications of diabetes; acute and chronic infections; stress state; anemia; hematologic disorders; surgery; tumor; pregnancy; history of liver and kidney disease; alcoholism; no severe bleeding within 6 months; no history of iron administration; cardiac, hepatic, renal insufficiency, and other endocrine diseases; and an ABI >1.3. The study was approved by the Ethics Committee of Shanghai Fengxian District Central Hospital and the procedures followed were in accordance with the Declaration of Helsinki. All patients signed an informed consent form.
The cases studied were all inpatients and the medical histories, including histories of smoking, hypertension (blood pressure ≥ 140/90 mmHg measured 3 times at different times at rest), cardiovascular and cerebrovascular diseases, and duration of diabetes, blood pressure, height (m), and weight (kg), were recorded and the body mass index (BMI, weight/height2) was calculated. HbA1c, total cholesterol (TC), triglycerides (TG), high-density lipoprotein-cholesterol (HDL-C), LDL-C, hemoglobin (Hb), white blood cell (WBC) count, and hypersensitive C-reactive protein (hs-CRP) were measured.
Serum hepcidin and SF were measured by double-antibody sandwich ABC-ELISA. An enzyme-linked immunosorbent assay (ELISA) was used to detect Fe and total iron-binding capacity (TIBC). The transferrin saturation (TS) was calculated as Fe/TIBC*100%. The kits were purchased from the Shanghai Xitang Company. The assay was performed according to the kit instructions and the absorbance was measured at 450 nm (Denley Dragon Wellscan MK3; Thermo Fisher Scientific, Waltham, MA, USA).
All subjects underwent an ABI determination at rest using an ES-100 V3 handheld Doppler flow detector (Japan). The same staff followed the device instructions. The lower of the two ABIs was used for diagnosis. The 2019 edition of the Chinese Diabetic Foot Prevention and Treatment Guidelines14 was used to determine the LEAD criterion, and the results showed that a resting ABI ≤ 0.9 was consistent with LEAD. Patients (0.9 < ABI ≤ 1.3) who conducted an ABI exercise load test and had a post-exercise ABI > 1.10 were classified as non-LEAD.15
The normally distributed measurement data are represented as the mean ± standard deviation (SD), and the statistical analysis was carried out with SPSS 22.0 software. The Student’s t-test was used to compare measurement data between two groups, while the chi-square test was used to compare categorical data. Continuous variable correlations were investigated using Pearson correlation analysis. For risk factor screening, we employed dichotomous logistic regression analysis. In determining the required sample size to achieve a 1-β = 0.80 and an α = 0.05, a two-sample t-test was conducted and the statistical power results indicated that a minimum of 74 subjects were required in each group. A P < 0.05 two-tailed was used to determine statistical significance.
There was no statistical difference between the two groups with respect to gender and BMI (P > 0.05; Table 1). Compared to the non-LEAD group, patients in the LEAD group were older (P < 0.001), had a longer duration of diabetes (P < 0.001), and had a higher proportion of patients with a combined history of smoking (P = 0.008), hypertension (P < 0.001), cardiovascular disease (P < 0.001), and diabetic retinopathy (P = 0.008; Table 1).
Table 1 Basic Characteristics Between Two Group (Mean ± SD)
Table 1 Basic Characteristics Between Two Group (Mean ± SD)
The t-test between the two groups revealed that the diastolic blood pressure, TC, and LDL-C levels in the non-LEAD group were higher than the LEAD group, while the Hb level was significantly lower and hepcidin was significantly higher in the LEAD group (P < 0.001). The differences between the two groups in the remaining test indexes were not statistically significant (Table 2).
Table 2 Comparison of Laboratory and Iron Metabolism Indexes Between the Two Groups (Mean ± SD)
Table 2 Comparison of Laboratory and Iron Metabolism Indexes Between the Two Groups (Mean ± SD)
Pearson correlation analysis revealed that ABI was negatively correlated with Fe, TS, and hepcidin, but not with ferritin and TIBC (Table 3). The results of partial correlation analysis with Fe, ferritin, TIBC, and TS as covariates showed that the serum hepcidin level was still negatively correlated with the ABI (r = −0.349, P < 0.001), but other iron metabolism indicators were not correlated with the ABI.
Table 3 Correlation Between Iron Metabolism and ABI
Table 3 Correlation Between Iron Metabolism and ABI
LEAD grouping variables were used as dependent variables, and the risk factors for diabetes mellitus complicated by LEAD included histories of smoking, hypertension, and cardiovascular disease, and gender, duration of diabetes, age, systolic blood pressure, diastolic blood pressure, BMI, TG, TC, HDL-C, LDL-C, WBC count, hs-CRP, HbA1c, Hb, Fe, SF, TIBC, TS, and hepcidin as independent variables for dichotomous logistic regression analysis.14 The results showed that histories of smoking, hypertension, and cardiovascular disease, and duration of diabetes, age, hs-CRP, HbA1c, and hepcidin were independent risk factors for the development of LEAD in patients with T2DM (Table 4).
Table 4 Logistic Regression Analysis of Risk Factors for LEAD in Patients with T2DM
Table 4 Logistic Regression Analysis of Risk Factors for LEAD in Patients with T2DM
LEAD is a typical chronic consequence of T2DM. According to the China DIA-LEAD research, the prevalence of LEAD among T2DM patients > 50 years of age in China is 21.2%, with a rate of missed diagnoses of 55.7%.16 LEAD is a component of peripheral arterial disease, which can result in ischemic ulcerations and lower-limb amputation. According to the findings of a 2012 diabetic foot survey in China, the proportion of patients with diabetic foot mixed with LEAD was 59%.17 Because LEAD frequently co-exists with cardiovascular disorders, such as myocardial ischemia and cerebral infarction, LEAD may be useful in predicting the development of arterial thrombotic diseases.18
Iron is used as a strong oxidant and generates large amounts of oxygen radicals through the Haber-Weiss reaction, thus causing peroxidation of intracellular lipids, damage to vascular endothelial cells, and lipid deposition on the vessel wall, which leads to plaque formation and affects the stability of atheromatous plaques.19,20 Hepcidin is a low molecular weight antibacterial agent discovered by Krause et al21 and Park et al22 in 2000 and 2001, respectively. Hepcidin is a low molecular antibacterial polypeptide synthesized in the liver and expressed in macrophages, adipocytes, and other systemic locations. Hepcidin inhibits intestinal iron uptake and iron release from the monocyte-macrophage system and is an important iron regulator.
Our study showed that within the T2DM population, hepcidin levels were significantly higher in the LEAD group compared to the non-LEAD group, and were negatively correlated with the ABI after excluding other influencing factors. Moreover, in a logistic regression analysis of risk factors for LEAD, elevated serum hepcidin levels were shown to be one of the risk factors for the development of LEAD in T2DM patients. Other indicators of iron metabolism in the body were not correlated with the ABI and were not influential factors for the development of LEAD. The correlation between hepcidin levels and atherosclerosis is also supported by reports of clinical studies conducted in different populations.23–26
Valenti et al23 observed the correlation between hepcidin and carotid intima-media thickness in 143 patients with non-alcoholic fatty liver disease (NAFLD) and found that hepcidin levels were associated with carotid plaque formation. Elevated hepcidin levels were also found to increase carotid intima-media thickness in patients with diabetic nephropathy in a study,24 and similar results were obtained in patients with chronic kidney disease on hemodialysis.25 Another study showed that in a community population, elevated hepcidin levels increased carotid-femoral pulse wave velocity, suggesting that hepcidin is associated with atherosclerosis.26 Ferritin and transferrin saturation are modestly associated with peripheral arterial disease, especially in people with high cholesterol levels.27
Li et al28 reported that hepcidin is strongly associated with all-cause mortality in patients with acute coronary syndromes and may be a predictor of the risk of developing coronary artery disease in patients with hepcidin. The ratio of serum hepcidin-to-ferritin in postmenopausal women is significantly and negatively correlated with the resting ABI, suggesting that hepcidin may be involved in the development of atherosclerosis in postmenopausal women.29 The association between hepcidin and atherosclerosis has also been found in animal studies, where some researchers fed high-fat food to hepcidin receptor gene knockout rats. The hepcidin receptor gene-deficient rats exhibited a significant reduction in atherosclerosis compared to the control group.30
The mechanisms by which hepcidin is involved in the development of atherosclerosis are still unclear. It has been shown that hepcidin increases iron deposition in macrophages within atherosclerotic plaques, which enhances lipid peroxidation in macrophages, promotes foam cell formation, and makes it easier to form unstable arterial plaques.31,32 In addition, as hepcidin production in the liver decreases, the intracellular iron content of macrophages decreases, the cholesterol efflux capacity increases, and foam cells are less likely to form, thus reducing the formation of atherosclerosis.33 The variability of blood hepcidin levels in diabetic patients is connected to inflammatory stimulation, anemia, and nutritional status, suggesting that hepcidin might be an early predictor of inflammation in diabetes patients with peripheral artery disease. Furthermore, an increase in hepcidin is a risk factor for diabetic foot ulcers.34
The results of this study showed lower cholesterol and LDL-C levels in the LEAD group than the non-LEAD group, which is inconsistent with the results of a previous study on arterial lesions;35 we consider that this finding may be related to the fact that patients in the LEAD group would more aggressively use lipid-lowering drugs. T2DM patients have impaired liver function, which affects the production of regulator proteins involved in iron metabolism. As a result, dysregulated iron metabolism may result in chronic illness, anemia, or iron-loading anemia deficiency.36,37 Hepcidin levels are changed in T2DM patients and are disproportionately impacted by weight. Furthermore, despite having higher iron storage, individuals with T2DM present with subclinical anemia.37
High plasma homocysteine (Hcy) concentrations are also linked to new-onset peripheral artery disease ([PAD] OR=2.08, 95% CI: 1.08–4.03, P=0.030).38 Endothelial dysfunction, oxidative stress, and vascular remodeling are all pathogenic processes involving Hcy.39 Smokers with high Hcy concentrations are significantly more likely than non-smokers with normal Hcy concentrations to have new-onset PAD (OR=4.44, 95% CI: 1.77–11.12, P=0.001). Diabetes has a significant effect on PAD when combined with a high Hcy concentration (OR=3.67, 95% CI: 1.25–10.80, P=0.018).38 In descending order of strength, a history of cardiovascular disease, smoking, and hypertension, and HbA1c levels, hs-CRP levels, duration of diabetes, hepcidin levels, and age were all connected to the risk of LEAD. The hepcidin/ferritin ratio was shown to be superior to hepcidin alone as a risk marker in a meta-analysis.40
Due to the limited sample size and several contributing factors that impact LEAD, it was not feasible to establish whether there was a causal link between hepcidin and LEAD in this study. To answer this, further prospective research will be required.
A high serum hepcidin level is one of the risk factors for the development of LEAD in T2DM patients, and it may have a role in the onset and progression of LEAD in T2DM patients.
Fund Project of Science and Technology Commission of Shanghai Fengxian District, Project of Social Science and Technology Development (No. 20171034).
The authors declare no competing interests in this work.
1. Chinese Diabetes Society. Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition). Chin J Diabetes Mellit. 2021;37(04):311–398.
2. Saeedi P, Petersohn I, Salpea P; et al.; IDF diabetes atlas committee. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843. doi:10.1016/j.diabres.2019.107843
3. Lu X, Sun J, Bai JJ, Ming Y, Chen LR. Investigation and analysis of lower extremity arterial disease in hospitalized elderly type 2 diabetic patients. Int J Nurs Sci. 2018;5(1):45–49. doi:10.1016/j.ijnss.2017.10.020
4. Guan H, Li YJ, Xu ZR, et al. Prevalence and risk factors of peripheral arterial disease in diabetic patients over 50 years old in China. Chin Med Sci J. 2007;22(2):83–88.
5. Adler A, Stevens R, Neil A, Irene MS, Andrew JMB, Rury RH. UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care. 2002;25:894–899. doi:10.2337/diacare.25.5.894
6. Wang Z, Fang S, Ding S, Tan Q, Zhang X. Research progress on relationship between iron overload and lower limb arterial disease in type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2022;15:2259–2264. doi:10.2147/DMSO.S366729
7. Pigeon C, Ilyin G, Courselaud B, et al. A new mouse liver-specific gene, encoding protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem. 2001;276(11):7811–7819. doi:10.1074/jbc.M008923200
8. Afsar RE, Kanbay M, Ibis A, Afsar B. In-depth review: is hepcidin a marker for the heart and the kidney? Mol Cell Biochem. 2021;476(9):3365–3381. doi:10.1007/s11010-021-04168-4
9. Liu J, Li Q, Yang Y, Ma L. Iron metabolism and type 2 diabetes mellitus: a meta-analysis and systematic review. J Diabetes Investig. 2020;11(4):946–955. doi:10.1111/jdi.13216
10. Vela D, Sopi RB, Mladenov M. Low hepcidin in type 2 diabetes mellitus: examining the molecular links and their clinical implications. Can J Diabetes. 2018;42(2):179–187. doi:10.1016/j.jcjd.2017.04.007
11. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306(5704):2090–2093. doi:10.1126/science.1104742
12. Sebastian G, Wilkinso N, Pantopoulo K. Pharmacological targeting of the hepcidin/ferroportin axis. Front Pharmacol. 2016;7:160. doi:10.3389/fphar.2016.00160
13. Wunderer F, Traeger L, Sigurslid HH, Meybohm P, Bloch DB, Malhotra R. The role of hepcidin and iron homeostasis in atherosclerosis. Pharmacol Res. 2020;153:104664. doi:10.1016/j.phrs.2020.104664
14. Chinese Diabetes Soiety, Chinese Society of Infectious Diseases, Chinese Society for Tissue Repair and Regeneration. Chinese guideline on prevention and management of diabetic foot (2019 edition) (II). Chin J Diabetes Mellitus. 2019;11(3). doi:10.3760/cma.j.issn.1674-5809.2019.03.005
15. Alqahtani KM, Bhangoo M, Vaida F, Denenberg JO, Allison MA, Criqui MH. Predictors of change in the ankle brachial index with exercise. Eur J Vasc Endovasc Surg. 2018;55(3):399–404. doi:10.1016/j.ejvs.2017.12.004
16. Zhang X, Ran X, Xu Z, et al. Epidemiological characteristics of lower extremity arterial disease in Chinese diabetes patients at high risk: a prospective, multicenter, cross-sectional study. J Diabetes Complications. 2018;32(2):150–156. doi:10.1016/j.jdiacomp.2017.10.003
17. Ban YJ, Ran XW, Yang C, et al. Comparison of clinical characteristics and medical costs of patients with diabetic foot ulcer in some provinces of China. Chin J Diabetes Mellitus. 2014;6(7):July. doi:10.3760/cma.j.issn.1674-5809.2014.07.005
18. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295(2):180–189. doi:10.1001/jama.295.2.180
19. Minqin R, Rajendran R, Pan N, et al. The iron chelator desferrioxamine inhibits atherosclerotic lesion development and decreases lesion iron concentrations in the cholesterol-fed rabbit. Free Radic Biol Med. 2005;38(9):1206–1211. doi:10.1016/j.freeradbiomed.2005.01.008
20. Lee HT, Chiu LL, Lee TS, et al. Dietary iron restriction increases plaque stability in apolipoprotein-e-deficient mice. J Biomed Sci. 2003;10(5):510–517. doi:10.1007/BF02256112
21. Krause A, Neitz S, Magert HJ, et al. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett. 2000;480:147–150. doi:10.1016/s0014-5793(00)01920-7
22. Park CH, Valore EV, Waring AJ, et al. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. 2001;276:7806–7810. doi:10.1074/jbc.M008922200
23. Valenti L, Swinkels DW, Burdick L, et al. Serum ferritin levels are associated with vascular damage in patients with nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2011;21(8):568–575. doi:10.1016/j.numecd.2010.01.003
24. Li H, Feng SJ, Su LL, et al. Serum hepcidin predicts uremic accelerated atherosclerosis in chronic hemodialysis patients with diabetic nephropathy. Chin Med J. 2015;128(10):1351–1357. doi:10.4103/0366-6999.156781
25. Kali A, Yayar O, Erdogan B, et al. Is hepcidin-25 a predictor of atherosclerosis in hemodialysis patients? Hemodial Int. 2016;20(2):191–197. doi:10.1111/hdi.12355
26. Wang X, Sheng L, Ye P, et al. The association between Hepcidin and arterial stiffness in a community-dwelling population. Lipids Health Dis. 2018;17:1. doi:10.1186/s12944-018-0866-6
27. Menke A, Fernández-Real JM, Muntner P, Guallar E. The association of biomarkers of iron status with peripheral arterial disease in US adults. BMC Cardiovasc Disord. 2009;9:34. doi:10.1186/1471-2261-9-34
28. Li X, Ding D, Zhang Y, et al. Associations of plasma hepcidin with mortality risk in patients with coronary artery disease. Oncotarget. 2017;8(65):109497–109508. doi:10.18632/oncotarget.22722
29. Galesloot TE, Holewijn S, Kiemeney LA, et al. Serum hepcidin is associated with presence of plaque in postmenopausal women of a general population. Arterioscler Thromb Vasc Biol. 2014;34(2):446–456. doi:10.1161/ATVBAHA.113.302381
30. Malhotra R, Wunderer F, Barnes HJ, et al. Hepcidin deficiency protects against atherosclerosis. Arterioscler Thromb Vasc Biol. 2019;39(2):178–187. doi:10.1161/ATVBAHA.118.312215
31. Finn AV, Nakano M, Polavarapu R, et al. Hemoglobin directs macrophage differentiation and prevents foam cell formation in human atherosclerotic plaques. J Am Coll Cardiol. 2012;59(2):166–177. doi:10.1016/j.jacc.2011.10.852
32. Sullivan JL. Macrophage iron, hepcidin, and atherosclerotic plaque stability. Exp Biol Med. 2007;232(8):1014–1020. doi:10.3181/0703-MR-54
33. Saeed O, Otsuka F, Polavarapu R, et al. Pharmacological suppression of hepcidin increases macrophage cholesterol efflux and reduces foam cell formation and atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32(2):299–307. doi:10.1161/atvbaha.111.240101
34. Qianru LI, Yuan JJ, Luo YF. Analysis of serum hepcidin levels and related factors in patients with diabetic lower extremity vascular disease and foot ulcer. J Chin Physician. 2021;12:674–678.
35. Pereira C, Miname M, Makdisse M, Kalil Filho R, Santos RD. Association of peripheral arterial and cardiovascular diseases in familial hypercholesterolemia. Arq Bras Cardiol. 2014;103(2):118–123. doi:10.5935/abc.20140097
36. Madu AJ, Ughasoro MD. Anaemia of chronic disease: an in-depth review. Med Princ Pract. 2017;26:1–9. doi:10.1159/000452104
37. de Las Cuevas Allende R, Díaz de Entresotos L, Conde Díez S. Anaemia of chronic diseases: pathophysiology, diagnosis and treatment. Med Clin. 2021;156(5):235–242. doi:10.1016/j.medcli.2020.07.035
38. Liu M, Fan F, Liu B, et al. Joint effects of plasma homocysteine concentration and traditional cardiovascular risk factors on the risk of new-onset peripheral arterial disease. Diabetes Metab Syndr Obes. 2020;13:3383–3393. doi:10.2147/DMSO.S267122
39. Zaric BL, Obradovic M, Bajic V, Haidara MA, Jovanovic M, Isenovic ER. Homocysteine and hyperhomocysteinaemia. Curr Med Chem. 2019;26(16):2948–2961. doi:10.2174/0929867325666180313105949
40. Ndevahoma F, Mukesi M, Dludla PV, Nkambule BB, Nepolo EP, Nyambuya TM. Body weight and its influence on hepcidin levels in patients with type 2 diabetes: a systematic review and meta-analysis of clinical studies. Heliyon. 2021;7(3):e06429. doi:10.1016/j.heliyon.2021.e0649
© 2022 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.
© Copyright 2022 • Dove Press Ltd • software development by maffey.com • Web Design by Adhesion
The opinions expressed in all articles published here are those of the specific author(s), and do not necessarily reflect the views of Dove Medical Press Ltd or any of its employees.
Dove Medical Press is part of Taylor & Francis Group, the Academic Publishing Division of Informa PLC
Copyright 2017 Informa PLC. All rights reserved. This site is owned and operated by Informa PLC ( “Informa”) whose registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36